A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 4 of the 20 sources its claims cite were checked for support.
Abstract
Introduction: Major depressive disorder (MDD) is a globally prevalent chronic psychiatric illness with a significant disease impact. As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant. This study aimed to quantify healthcare costs associated with treatment resistant depression (TRD) in the UK. Methods: A retrospective chart review of patients with TRD was conducted in primary and secondary care settings over a 2 year period. Data abstracted from medical records of patients included demographics, clinical characteristics and healthcare resource utilization (HCRU; number of consultations, use of Crisis Resolution and Home Treatment Teams [CRHTTs], non-drug and drug interventions, and hospitalizations). HCRU per patient per month (28 days) was calculated for three health states: major depressive episode (MDE), remission and recovery. Unit costs were from the British National Formulary (BNF) and the Personal Social Services Research Unit (PSSRU). Results: A total of 295 patients with TRD were recruited between January 2016 and May 2018. The mean age of the total sample was 43.3 years; 60.3% were female. Costs per patient, per 28 days, were highest in the MDE state, with the average cost (£992) mainly driven by consultations, non-drug treatment, hospitalizations and CRHTT, with a considerable fall in costs as patients moved into remission and subsequent recovery. Conclusion: The results suggest that antidepressant treatments for TRD that are more effective in reducing the time spent in an MDE health state, and helping patients achieve remission and recovery, are essential for reducing the overall HCRU and costs in patients with TRD. Cost of TRD in the UK Strengths and limitations of this study This observational study of TRD is the first to assess the HCRU impact associated with different predefined health states. Using retrospective data from both primary and secondary care physicians from regions across the UK ensures a representative real-world patient population. One limitation is that the selection of patients is based on criteria that define TRD that rely on physician judgement. Although the study captures direct HCRU costs, the indirect costs of lost productivity and care are not included in the overall burden. This study has defined the current clinical management of patients with TRD in the UK and provides an estimate of the associated HCRU and associated costs. © 2021 Johnson & Johnson. Published by Informa UK Limited, trading as Taylor & Francis Group.
Overview
CoChat Summary
TL;DR
This retrospective UK chart review of 295 patients with treatment-resistant depression found direct NHS costs per 28 days were highest during a major depressive episode (£992), falling to £254 in remission and £99 in recovery. The authors conclude that treatments more effective at shortening MDE and achieving remission/recovery would reduce healthcare resource use and costs.
Key findings
- In 295 patients with TRD, mean age was 43.3 years and 60.3% were female; 30 psychiatrists and 9 GPs contributed data.
- Mean HCRU cost per patient per 28 days was £992 in MDE, £254 in remission, and £99 in recovery; non-drug HCRU was £980, £164, and £84, respectively.
- MDE cost drivers included CRHTT (£326 vs £18 in remission/recovery), hospitalizations (£380 vs £42 remission and £12 recovery), primary care visits (£52), and specialist visits (£11) per 28 days.
- Drug treatment costs were relatively low and highest in remission (£107) versus MDE (£38) and recovery (£28); the discussion reports an annual cost for patients with TRD of approximately £11,900.
Methods
- Retrospective chart review in UK primary and secondary care; patients classified as TRD by treating physicians in the index window 1 January 2016–31 May 2016, with data recorded for 2 years until 31 May 2018.
- 30 psychiatrists and 9 GPs were recruited, each identifying up to 10 eligible patients, yielding 295 patients; HCRU data included consultations, CRHTT use, ED admissions, hospitalizations, antidepressants, other psychiatric medications, and non-drug treatments.
- Descriptive statistics were performed in STATA version 15.0 with no formal hypothesis testing; costs per patient per 28 days were calculated for MDE, remission, and recovery using unit costs from the BNF and PSSRU.
Limitations
- Paper-stated: TRD selection relies on physician judgement; indirect costs of lost productivity and informal care are not included; the design relies on physician accuracy in completing eCRFs; observational retrospective health-state determination may limit precision; selection bias is possible because patients visiting more often were more likely to be included; the sample is heterogeneous with wide result distributions.
- Paper-stated: missing HCRU data items were set to zero to preserve sample sizes, and the authors acknowledge reported averages might underestimate actual resource utilization.
- Evident from the text: no formal hypothesis testing was performed, so health-state cost differences are descriptive only.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
3 Valid · 0 Not valid · 14 Not checked · 59 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with a considerable fall in costs as patients moved into remission and subsequent recovery.”
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the average cost PPPM of all HCRU of patients in the MDE state (£991.82)was mainly driven by the consultations, non-drug treatment, hospitalizations and CRHTT”
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients made an average of 0.05 ± 0.13 suicide attempts during the initial MDE.”
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Healthcare resource utilization
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“More specialist visits were recorded for patients during the MDE state (0.36 ± 0.23) than either remission or recovery states (0.21 ± 0.22 and 0.21 ± 0.34, respectively) (Table 3).”
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Healthcare resource utilization
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The greatest number of hospitalizations was reported in the MDE state with an average of 1.40 ± 4.15 nights.”
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Healthcare resource utilization
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
15 more claims
Create a free account to see all 76 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 29
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Monthly cost of healthcare resource utilization
“costs for primary care and specialist visits (£52 and £11 per 28 days, respectively, exceeding the £31 and £7, respectively, for remission and £7 and £3 for recovery)”
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Declaration of funding
“| Primary care visits | 10.82 (17.93) | 7.12 (16.86) | 3.44 (8.84) | | Specialist visits | 52.32 (77.09) | 30.71 (32.81) 30.18 (49.43) | |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Strengths and limitations
“whilst three quarters of the patients were unemployed or retired”
§ A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom > Study population
“with 42.0% of patients unemployed or retired (Table 2).”
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
The increasing burden of depression
Briley, M., & Lépine (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19617 · Cited by 1,211
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citation(2016) · City Research Online (City University London) · Cited by 747
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Research works printed but not linked: 4
- NICE. National Institute for Health and Care Excellence: Clinical Guidelines. Depression in adults: recognition and management. London: National Institute for Health and Care Excellence (UK); 2009.
- Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ comparative effectiveness reviews. second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
- EMA. Guideline on clinical investigation of medicinal products in the treatment of depression. European Medicines Agency; 2013.
- Curtis L. Unit costs of health and social care 2010. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 2010.
Cited by
McCrone, P., Fisher, H., Knight, C., Harding, R., Schlag, A. K., Nutt, D. J., & Neill, J. C. (2023) · Psychological Medicine · doi:10.1017/s0033291723001411 · Cited by 42
“The healthcare costs associated with relapse, remission, and not relapsing were adapted from a recent UK casenote review by Denee et al. (2021).”
BackgroundSelf-citationEsketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Fu, D., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05017-y · Cited by 23
“In patients with treatment-resistant depression, healthcare resource utilization (HRU) is lower during remission than during a major depressive episode [33].”
BackgroundSelf-citationGillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., et al. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00306-2 · Cited by 16
“These results are comparable to findings from a retrospective cohort study conducted in the UK [27] and international reports on quality of life and costs in function of disease severity and treatment efficacy [9, 10, 28].”
ResultPappa, S., Shah, M., Young, S., Anwar, T., & Ming, T. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.11.022 · Cited by 21
Self-citationForthman, K. L., Kuplicki, R., Thompson, W. K., Nemeroff, C. B., Si, Y., Fan, C. C., & Paulus, M. P. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119858 · Cited by 8
Metadata
- Authors
- Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D.
- Affiliations
- Janssen (United Kingdom) (GB)
- Adelphi Group (United Kingdom) (GB)
- Adelphi Real World
- Janssen Scientific Affairs (United States) (US)
- University of Greenwich (GB)
- The Tavistock and Portman NHS Foundation Trust (GB)
- Corresponding author
- Zhang, Qiaoyi
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2021-01-25
- Volume
- 37
- Issue
- 2
- Pages
- 311-319
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W3110538873
- Cited by
- 12
- References
- 33
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Janssen
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, major depressive disorder, healthcare resource utilization, health care costs, major depressive episode, remission, recovery, hospitalization, antidepressant treatment, primary and secondary care
- MeSH terms
- Adolescent, Adult, Antidepressive Agents, Major Depressive Disorder, Female, United Kingdom, Hospitalization, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Referral and Consultation, Retrospective Studies, Health Care Costs, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. https://app.cochat.ai/papers/10.1080/03007995.2020.1857580
- The paper
- Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021). A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2020.1857580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.




